Inspire Medical Systems (NYSE:INSP) Shares Gap Up on Earnings Beat

Posted by Francis Steltz on Aug 4th, 2026

Shares of Inspire Medical Systems, Inc. (NYSE:INSP – Get Free Report) gapped up prior to trading on Tuesday after the company announced better than expected quarterly earnings. The stock had previously closed at $52.22, but opened at $64.16. Inspire Medical Systems shares last traded at $63.1630, with a volume of 333,851 shares trading hands.

The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.38. The company had revenue of $200.58 million for the quarter, compared to the consensus estimate of $194.72 million. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The firm’s revenue was down 7.6% compared to the same quarter last year. During the same period last year, the business posted $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS.

Key Inspire Medical Systems News

Here are the key news stories impacting Inspire Medical Systems this week:

Positive Sentiment: Second-quarter earnings and revenue beat expectations: Inspire reported adjusted EPS of $0.14, versus the consensus estimate of a $0.24 loss, while revenue reached $200.6 million, above expectations of $194.7 million. Inspire Medical Systems Q2 Earnings and Revenues Beat Estimates
Positive Sentiment: Full-year guidance was raised: FY2026 EPS is now projected at $1.05-$1.45, well above the $0.91 analyst consensus, while revenue guidance is $835 million-$875 million. The improved outlook was a key driver of investor optimism. Inspire Announces Q2 Results and Raised Guidance
Positive Sentiment: Analyst sentiment improved: Oppenheimer upgraded INSP from “market perform” to “outperform” and set an $85 price target. Robert W. Baird also raised its target from $54 to $59, although it retained a neutral rating. Analyst Ratings and Price Targets
Neutral Sentiment: The company’s strategic growth plan and second-quarter earnings call may provide additional details on demand, product adoption and future expansion, but the supplied reports do not quantify new initiatives. Inspire Q2 2026 Earnings Call Transcript
Negative Sentiment: Year-over-year comparisons remain weak: Revenue declined 7.6% from the prior-year quarter, and EPS fell from $0.45 to $0.14. This deterioration likely explains why Baird remains cautious despite raising its target.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on INSP shares. Oppenheimer upgraded shares of Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 price objective on the stock in a research note on Tuesday. Summit Redstone set a $39.00 target price on shares of Inspire Medical Systems in a research note on Friday, May 22nd. UBS Group started coverage on shares of Inspire Medical Systems in a report on Tuesday, July 28th. They issued a “sell” rating and a $39.00 price target for the company. JPMorgan Chase & Co. decreased their price target on shares of Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 5th. Finally, Evercore downgraded shares of Inspire Medical Systems from an “outperform” rating to an “in-line” rating and set a $40.00 price objective on the stock. in a report on Tuesday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $70.06.

View Our Latest Stock Report on Inspire Medical Systems

Institutional Investors Weigh In On Inspire Medical Systems

Several large investors have recently modified their holdings of the stock. CWM LLC raised its holdings in shares of Inspire Medical Systems by 216.1% in the 4th quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after buying an additional 242 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Inspire Medical Systems by 1,115.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock valued at $33,000 after buying an additional 580 shares in the last quarter. Havemeyer Place LP acquired a new stake in Inspire Medical Systems in the 4th quarter valued at $39,000. V Square Quantitative Management LLC acquired a new stake in Inspire Medical Systems in the 4th quarter valued at $40,000. Finally, Smartleaf Asset Management LLC grew its position in Inspire Medical Systems by 84.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after acquiring an additional 205 shares during the period. 94.91% of the stock is currently owned by institutional investors.

Inspire Medical Systems Stock Up 21.1%

The business has a 50-day simple moving average of $46.15 and a two-hundred day simple moving average of $55.17. The stock has a market capitalization of $1.82 billion, a P/E ratio of 14.08, a PEG ratio of 5.08 and a beta of 0.70.

About Inspire Medical Systems

(Get Free Report)

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.